The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders
Open accessAbstract
Mutations in the gene encoding the lysosomal enzyme glucocerebrosidase, known to cause Gaucher disease (GD), are a risk factor for the development of Parkinson disease (PD) and related disorders. This association is based on the concurrence of parkinsonism and GD, the identification of glucocerebrosidase mutations in cohorts with PD from centers around the world, and neuropathologic findings. The contribution of glucocerebrosidase to the development of parkinsonian pathology was explored by studying seven brain samples from subjects carrying glucocerebrosidase mutations with pathologic diagnoses of PD and/or Lewy body dementia. Three individuals had GD and four were heterozygous for glucocerebrosidase mutations. All cases had no known family history of PD and the mean age of disease onset was 59 years (range 42–77). Immunofluorescence studies on brain tissue samples from patients with parkinsonism associated with glucocerebrosidase mutations showed that glucocerebrosidase was present in 32–90% of Lewy bodies (mean 75%), some ubiquitinated and others non-ubiquitinated. In samples from seven subjects without mutations, <10% of Lewy bodies were glucocerebrosidase positive (mean 4%). This data demonstrates that glucocerebrosidase can be an important component of α-synuclein-positive pathological inclusions. Unraveling the role of mutant glucocerebrosidase in the development of this pathology will further our understanding of the lysosomal pathways that likely contribute to the formation and/or clearance of these protein aggregates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“All, but one had advanced LB pathology, consistent with Braak stages V–VI [3].”
ResultSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationImpaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · cited 1×
“Furthermore, α-synuclein can be selectively translocated into the lysosomes for degradation by chaperone-mediated autophagy and aggregated forms of α-synuclein may be degraded by lysosomes [6].”
BackgroundGlucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Gai, W. P., Yuan, H. X., Li, X. Q., Power, J. T. H., Blumbergs, P. C., & Jensen, P. H. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7527 · Cited by 272 · cited 1×
“Like GC, lipids are located in the core of brain stemtype LBs and are observed diffusely in cortical LBs [8], and hence, abnormal lipid deposition could also play a role in GBA-associated parkinsonism.”
Cited by
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
The link between the GBA gene and parkinsonism
Sidransky, E., & Lopez, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70190-4 · Cited by 583
Self-citationSchöndorf, D. C., Aureli, M., McAllister, F. E., Hindley, C. J., Mayer, F., Schmid, B., Sardi, S. P., Valsecchi, M., Hoffmann, S., Schwarz, L. K., et al. (2014) · Nature Communications · doi:10.1038/ncomms5028 · Cited by 543
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M. (2014) · Brain · doi:10.1093/brain/awt367 · Cited by 475
Self-citationThe Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders
Wakabayashi, K., Tanji, K., Odagiri, S., Miki, Y., Mori, F., & Takahashi, H. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8280-y · Cited by 479
A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies
Nalls, M. A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I. G., Chinnery, P. F., Morris, C. M., Theuns, J., Crosiers, D., Cras, P., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1925 · Cited by 439
Self-citationDehay, B., Ramirez, A., Martinez-Vicente, M., Perier, C., Canron, M.-H., Doudnikoff, E., Vital, A., Vila, M., Klein, C., & Bezard, E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112368109 · Cited by 379
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature
Schneider, S. A., & Alcalay, R. N. (2017) · Movement Disorders · doi:10.1002/mds.27193 · Cited by 342
Lysosomal impairment in Parkinson's disease
Dehay, B., Martinez‐Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R., Klein, C., Vila, M., & Bezard, E. (2013) · Movement Disorders · doi:10.1002/mds.25462 · Cited by 340
McNeill, A., Magalhaes, J., Shen, C., Chau, K.-Y., Hughes, D., Mehta, A., Foltynie, T., Cooper, J. M., Abramov, A. Y., Gegg, M., et al. (2014) · Brain · doi:10.1093/brain/awu020 · Cited by 321
Sardi, S. P., Clarke, J., Kinnecom, C., Tamsett, T. J., Li, L., Stanek, L. M., Passini, M. A., Grabowski, G. A., Schlossmacher, M. G., Sidman, R. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108197108 · Cited by 319
The neuropathology of genetic Parkinson's disease
Poulopoulos, M., Levy, O. A., & Alcalay, R. N. (2012) · Movement Disorders · doi:10.1002/mds.24962 · Cited by 311
α‐Synuclein oligomers and clinical implications for Parkinson disease
Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M., & Lang, A. E. (2013) · Annals of Neurology · doi:10.1002/ana.23746 · Cited by 292
Winder-Rhodes, S. E., Evans, J. R., Ban, M., Mason, S. L., Williams-Gray, C. H., Foltynie, T., Duran, R., Mencacci, N. E., Sawcer, S. J., & Barker, R. A. (2013) · Brain · doi:10.1093/brain/aws318 · Cited by 290
Ferreira, C. R., & Gahl, W. A. (2017) · Translational Science of Rare Diseases · doi:10.3233/trd-160005 · Cited by 263
GBA Variants and Parkinson Disease: Mechanisms and Treatments
Smith, L., & Schapira, A. H. V. (2022) · Cells · doi:10.3390/cells11081261 · Cited by 256
HDL and cholesterol handling in the brain
Vitali, C., Wellington, C. L., & Calabresi, L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu148 · Cited by 254
Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease
Pitcairn, C., Wani, W. Y., & Mazzulli, J. R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.03.008 · Cited by 75
Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review
Gaubert, S., Hourregue, C., Mouton-Liger, F., Millot, P., Franco, M., Amar-Bouaziz, E., Aarsland, D., Hugon, J., & Paquet, C. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104856 · Cited by 26
Cosden, M., Jinn, S., Yao, L., Gretzula, C. A., Kandebo, M., Toolan, D., Hatcher, N. G., Ma, L., Lemaire, W., Adam, G. C., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105507 · Cited by 23
Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease
Schiffer, V., Santiago-Mujika, E., Flunkert, S., Schmidt, S., Farcher, M., Loeffler, T., Schilcher, I., Posch, M., Neddens, J., Sun, Y., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227077 · Cited by 11
Metadata
- Authors
- Goker-Alpan, O., Stubblefield, B. K., Giasson, B. I., & Sidransky, E.
- Venue
- Acta Neuropathologica
- Published
- 2010-09-14
- Volume
- 120
- Issue
- 5
- Pages
- 641-649
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W1964353444
- Cited by
- 181
- References
- 8
- FWCI
- 10.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.